CSIMarket Company Name, Ticker, Industry, else..
 
Absci Corp  (NASDAQ: ABSI)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $8.9100 $0.09 1.020%
Day's High: $9.100000381469727 Week Perf: 0.79 %
Day's Low: $ 8.57 30 Day Perf: -0.22 %
Volume (M): 2,487,120 52 Wk High: $ 12.06
Volume (M$): $ 0 52 Wk Avg: $4.95
Open: $8.81 52 Wk Low: $2.24



 Market Capitalization (Millions $) 1,403
 Shares Outstanding (Millions) 157
 Employees 140
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -121
 Cash Flow (TTM) (Millions $) -46
 Capital Exp. (TTM) (Millions $) 1

Business Description


Absci Corp is a biotechnology firm based in Vancouver, Canada. The company specializes in developing advanced technology platforms for the discovery and production of biotherapeutics, such as antibodies and vaccines. Their proprietary synthetic biology platform allows for rapid and high-throughput production of various biologics for research, clinical trials, and commercialization. Absci Corp's cutting-edge technologies enable the acceleration of drug development timelines and provide cost-effective solutions for biomanufacturing. The company is dedicated to advancing the field of biotechnology and improving healthcare outcomes through innovation and collaboration.


   Company Address: 18105 SE Mill Plain Blvd Vancouver 98683 WA
   Company Phone Number: 949-1041   Stock Exchange / Ticker: NASDAQ ABSI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
FTRE   -7.13%    
DNA        1.91% 
ILMN   -1.2%    
IMNM   -2.19%    
MRNA   -0.01%    
RXRX        1.18% 
• View Complete Report
   



Announcement

Abscis Bold Moves Innovations in Biotech and Revenue Growth Amid Financial Turbulence,

Published Sun, Dec 29 2024 11:06 PM UTC

In an era defined by rapid advancements in biotechnology, Absci Corporation is making significant strides that could alter the landscape of therapeutic development. At their recent 2024 Research and Development (R&D) Day, the company showcased promising updates from their proprietary pipeline, particularly with a new drug candidate, ABS-201 an innovative anti-Growth Hormone ...
Stock Market Announcement

Absci Corp Surges After Closing Highly Successful Public Offering, Strengthening AI Drug Creation Capabilities

Published Fri, Mar 1 2024 9:01 PM UTC

Extensive Absci Announces Successful Closure of Public Offering of Common Stock, Boosting Investor Confidence and Funding for AI Drug Creation
VANCOUVER, Wash., March 01, 2024 - Absci Corporation (Nasdaq: ABSI), a leading data-first generative AI drug creation company, has recently concluded its underwritten public offering of 19,205,000 shares of common stock at a pric...
Shares

Powering the Future of Drug Discovery: Absci's Innovative AI Public OfferingNote: The article refers to the $75.0 million proposed offering of common stock by Absci Corporation, as announced on February 27, 2024.

Published Tue, Feb 27 2024 9:01 PM UTC



In a recent press release, Absci Corporation (Nasdaq: ABSI), a pioneering data-first generative AI drug creation company, has announced its intention to launch an underwritten public offering of $75.0 million shares of its common stock. This move signifies Absci s commitment to accelerating the development of groundbreaking therapies by leveraging the power of arti...
Clinical Study

Absci Advances Groundbreaking Anti-TL1A Antibody ABS-101 with AI-Driven Design

Published Wed, Feb 21 2024 12:30 PM UTC

Absci, a leading synthetic biology company, has recently announced significant progress in the development of ABS-101, a promising anti-TL1A antibody. The company is utilizing its innovative Generative AI technology to design and optimize ABS-101, aiming to create a best-in-class therapeutic candidate. The initiation of IND-enabling studies marks a significant milestone in t...
Clinical Study

Breaking New Ground: ABS-101 and the Future's Promise of Best-in-Class Anti-TL1A Antibodies.

Published Mon, Jan 8 2024 12:02 PM UTC

In a recent announcement that has caused waves in the medical research community, Absci Corporation revealed it will present preclinical data for its much-anticipated ABS-101, a potential best-in-class Anti-TL1A Antibody Development Program, at the 42nd Annual J.P. Morgan Healthcare Conference. This burgeoning breakthrough in pharmaceuticals has surged new interest in develo...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 898.83
Price to Sales (Expected) -
Price to Book 5.7
PEG (TTM) -

Financial Strength Current
Quick Ratio 10.12
Working Capital Ratio 10.48
Leverage Ratio (MRQ) 0.09
Total Debt to Equity 0
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.82 $
Revenues (TTM) 0.01 $
Cash Flow (TTM) -
Cash 1.28 $
Book Value 1.56 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 11,150
Net Income per Employee (TTM) -864,836
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.01

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -10741.51 %
Net Margin (MRQ) -10443.4 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Absci's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.